高剂量糖皮质激素治疗接受地塞米松的重症COVID-19患者未消退急性呼吸窘迫综合征:多中心队列研究
这项前瞻性观察性队列研究纳入2020年9月至2021年2月大巴黎地区11个ICU连续收治的383例重症COVID-19相关未消退ARDS且已接受地塞米松初始治疗的患者,其中59例接受高剂量糖皮质激素(HDCT,≥1 mg/kg甲泼尼龙或等效剂量),324例未接受。主要终点90天死亡率HDCT组51%(30/59)vs 无HDCT组35.8%(116/324),未校正HR 1.60(95%CI 1.04-2.47,p=0.033),重叠权重倾向评分校正后HR 1.65(95%CI 1.03-2.63,p=0.036)。HDCT与呼吸机相关性肺炎风险增加无关(校正病因特异性HR 0.42,95%CI 0.15-1.16,p=0.09)。作者结论为在这类患者中HDCT导致更高的90天死亡率。
要点
- 重症COVID-19未消退ARDS且已接受地塞米松治疗者,HDCT(≥1 mg/kg甲泼尼龙或等效剂量)与90天死亡率升高相关:HDCT组51%(30/59)vs 无HDCT组35.8%(116/324)。
- 未校正分析HDCT与90天死亡率相关(HR 1.60;95%CI 1.04-2.47;p=0.033),重叠权重倾向评分校正后仍相关(校正HR 1.65;95%CI 1.03-2.63;p=0.036)。
- HDCT未增加呼吸机相关性肺炎风险(校正病因特异性HR 0.42;95%CI 0.15-1.16;p=0.09)。
- 研究为前瞻性观察性队列,纳入大巴黎地区11个ICU连续患者,HDCT组仅59例。
适用人群与场景
- 重症COVID-19相关未消退ARDS且已接受地塞米松初始治疗的成人ICU患者。
- 2020年9月至2021年2月大巴黎地区11个ICU连续收治的患者。
诊断标准与关键阈值
- 未消退ARDS:与严重急性呼吸综合征冠状病毒2感染相关,且已接受地塞米松初始治疗。
- HDCT定义:ICU期间接受≥1 mg/kg甲泼尼龙或等效剂量用于治疗未消退ARDS。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究,纳入11个ICU连续收治的383例患者(HDCT组59例,无HDCT组324例)。
- 主要终点90天死亡率:HDCT组30/59例(51%)vs 无HDCT组116/324例(35.8%)。
- 未校正分析:HDCT与90天死亡率相关(HR 1.60;95%CI 1.04-2.47;p=0.033)。
- 重叠权重倾向评分校正后:HDCT与90天死亡率相关(校正HR 1.65;95%CI 1.03-2.63;p=0.036)。
- 呼吸机相关性肺炎:HDCT与风险增加无关(校正病因特异性HR 0.42;95%CI 0.15-1.16;p=0.09)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在重症COVID-19未消退ARDS患者中,HDCT导致更高的90天死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the impact of high doses of corticosteroids (HDCT) in critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) who had been previously treated with dexamethasone as a standard of care.
DESIGN: Prospective observational cohort study. Eligible patients presented nonresolving ARDS related to severe acute respiratory syndrome coronavirus 2 infection and had received initial treatment with dexamethasone. We compared patients who had received or not HDCT during ICU stay, consisting of greater than or equal to 1 mg/kg of methylprednisolone or equivalent for treatment of nonresolving ARDS. The primary outcome was 90-day mortality. We assessed the impact of HDCT on 90-day mortality using univariable and multivariable Cox regression analysis. Further adjustment for confounding variables was performed using overlap weighting propensity score. The association between HDCT and the risk of ventilator-associated pneumonia was estimated using multivariable cause-specific Cox proportional hazard model adjusting for pre-specified confounders.
SETTING: We included consecutive patients admitted in 11 ICUs of Great Paris area from September 2020 to February 2021.
PATIENTS: Three hundred eighty-three patients were included (59 in the HDCT group, 324 in the no HDCT group).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: At day 90, 30 of 59 patients (51%) in the HDCT group and 116 of 324 patients (35.8%) in the no HDCT group had died. HDCT was significantly associated with 90-day mortality in unadjusted (hazard ratio [HR], 1.60; 95% CI, 1.04-2.47; p = 0.033) and adjusted analysis with overlap weighting (adjusted HR, 1.65; 95% CI, 1.03-2.63; p = 0.036). HDCT was not associated with an increased risk of ventilator-associated pneumonia (adjusted cause-specific HR, 0.42; 95% CI, 0.15-1.16; p = 0.09).
CONCLUSIONS: In critically ill COVID-19 patients with nonresolving ARDS, HDCT result in a higher 90-day mortality.
参考来源
- Lopinto J, Arrestier R, Peiffer B, et al. High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study. Crit Care Med. 2023. PMID: 37199534. doi:10.1097/CCM.0000000000005930
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。